Immunomodulatory effects of the fungicide Mancozeb in agricultural workers

被引:57
作者
Corsini, E
Birindelli, S
Fustinoni, S
De Paschale, G
Mammone, T
Visentin, S
Galli, CL
Marinovich, M
Colosio, C
机构
[1] Int Ctr Pesticides & Hlth Risk Prevent, I-20020 Busto Garolfo, Italy
[2] Univ Milan, Dept Pharmacol Sci, Toxicol Lab, I-20133 Milan, Italy
[3] Ist Clin Perfezionamento, Dept Occupat Hlth, I-20122 Milan, Italy
[4] UOPL Pavia, I-27058 Voghera, Italy
关键词
immunotoxicology; Mancozeb; fungicide; TNF-alpha; CD25; CD19; proliferative response; agricultural workers; biological monitoring;
D O I
10.1016/j.taap.2005.02.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Available data suggest that ethylenebisdithiocarbamates (EBDCs) may have immunomodulatory effects. This study aimed to investigate the immunological profile of farmers exposed to Mancozeb, an EBDC fungicide, through the determination of several serum, cellular, and functional immune parameters. Twenty-six healthy subjects entered the study, 13 vineyards exposed to Mancozeb and 13 unexposed controls. Exposure was assessed through the determination of ethylentiourea (ETU) in urine. Complete and differential blood count, serum immunoglobulins, complement fractions, autoantibodies, lymphocyte subpopulations, proliferative response to mitogens, natural killer (NK) activity, and cytokine production were measured. Post-exposure samples showed ETU urine concentration significantly higher than pre-exposure and control groups. A significant increase in CD19+ cells, both percentage and absolute number, and a significant decrease in the percentage of CD25+ cells were found in post-exposure samples compared to controls. A statistically significant increase in the proliferative response to phorbol myristate acetate plus ionomycin (PMA + ionomycin) was observed in the post-exposure group compared to controls and baseline, while a significant reduction in LPS-induced TNF-alpha release in post-exposure samples was observed. Overall, our results suggest that low-level exposure to Mancozeb has slight immunomodulatory effects, and point out a method adequate to reveal immune-modifications in workers occupationally exposed to potential immunotoxic compounds, based on a whole blood assay. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:178 / 185
页数:8
相关论文
共 23 条
  • [11] EVALUATION OF THE IMMUNOMODULATORY POTENTIAL OF DIETHYL DITHIOCARBAMATE DERIVATIVES
    LOMBARDI, P
    FOURNIER, M
    BERNIER, J
    MANSOUR, S
    NEVEU, P
    KRZYSTYNIAK, K
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1991, 13 (08): : 1073 - 1084
  • [12] Immunotoxicology: Clinical consequences
    Luster, MI
    [J]. TOXICOLOGY AND INDUSTRIAL HEALTH, 1996, 12 (3-4) : 533 - 535
  • [13] EXPERIMENTAL-STUDY ON CONTACT-DERMATITIS CAUSED BY DITHIOCARBAMATES MANEB, MANCOZEB, ZINEB, AND THEIR RELATED COMPOUNDS
    MATSUSHITA, T
    ARIMATSU, Y
    NOMURA, S
    [J]. INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 1976, 37 (03) : 169 - 178
  • [14] MORALES A, 1983, CANCER, V52, P667, DOI 10.1002/1097-0142(19830815)52:4<667::AID-CNCR2820520417>3.0.CO
  • [15] 2-C
  • [16] DISPARATE EFFECTS OF REPRESENTATIVE DITHIOCARBAMATES ON SELECTED IMMUNOLOGICAL PARAMETERS INVIVO AND CELL-SURVIVAL INVITRO IN FEMALE B6C3F1 MICE
    PADGETT, EL
    BARNES, DB
    PRUETT, SB
    [J]. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH, 1992, 37 (04): : 559 - 571
  • [17] IMMUNOTOXICOLOGICAL CHARACTERISTICS OF SODIUM METHYLDITHIOCARBAMATE
    PRUETT, SB
    BARNES, DB
    HAN, YC
    MUNSON, AE
    [J]. FUNDAMENTAL AND APPLIED TOXICOLOGY, 1992, 18 (01): : 40 - 47
  • [18] Dimethyldithiocarbamate inhibits in vitro activation of primary human CD4+ T lymphocytes
    Pyatt, DW
    Gruntmeir, J
    Stillman, WS
    Irons, RD
    [J]. TOXICOLOGY, 1998, 128 (02) : 83 - 90
  • [19] EFFECTS OF SODIUM DIETHYLDITHIOCARBAMATE, AZATHIOPRINE, CYCLOPHOSPHAMIDE, OR HYDROCORTISONE ACETATE ADMINISTERED ALONE OR IN ASSOCIATION FOR 4 WEEKS ON THE IMMUNE-RESPONSES OF BALB-C MICE
    RENOUX, G
    RENOUX, M
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1980, 15 (01): : 23 - 32
  • [20] RENOUX G, 1988, INT J IMMUNOPHARMACO, V4, P489